DNLI Stock Forecast: Denali Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$18
+1.37% on the day

The 21 Wall Street analysts covering Denali Therapeutics, Inc. hold a median 12-month price target of $35 — +89.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$2.9B
Ticker Nerd rank
61/ 100
Median analyst target
$35
Analysts covering
21
Revenue$3.6M
Operating income−$130.5M
Net income−$127.6M
Free cash flow−$126.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.5%
1M
−2.5%
YTD
+11.8%
1Y
+7.5%
From 52W high
−32.2%
From 52W low
+15.2%
$16
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Denali Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
61/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
80
Volatility
71
Value
68
Growth
67
Momentum
66
Issuance
51
Quality
47
Accruals
14

Revisions (80): Analysts have, on balance, been raising their forecasts.

Accruals (14): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DNLI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DNLI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26DNLIHigh $46Median $35Low $24

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says21 analysts
20
Buy
1
Hold
0
Sell
$24
Low
$35
Median
$46
High

The green dot is the last close — the median target sits +89.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
13 Nov 2026Morgan StanleyMaintainsOverweight$42 → $37
13 Nov 2026Wells FargoInitiatesOverweight$35
4 Nov 2026BTIGReiteratesBuy$39
4 Nov 2026Morgan StanleyMaintainsOverweight$40 → $42
4 Nov 2026WedbushMaintainsOutperform$23 → $24
25 Aug 2026B. Riley SecuritiesMaintainsBuy$30 → $35
7 Aug 2026UBSMaintainsBuy$25 → $34
23 July 2026Morgan StanleyMaintainsOverweight$35 → $36
16 July 2026Deutsche BankMaintainsBuy$31 → $35
13 July 2026JP MorganReinstatesOverweight$29
26 May 2026Morgan StanleyMaintainsOverweight—
14 May 2026Morgan StanleyMaintainsOverweight—
11 May 2026BTIGReiteratesBuy—
8 May 2026WedbushMaintainsOutperform—
22 Apr 2026Leerink PartnersMaintainsOutperform—
7 Apr 2026BairdMaintainsOutperform—
26 Mar 2026BairdMaintainsOutperform—
26 Mar 2026Goldman SachsMaintainsBuy—
26 Mar 2026HC Wainwright & Co.MaintainsBuy—
26 Mar 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DNLI.

Market Radar

This page is one stock. Monday covers all of them.

DNLI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DNLI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Denali Therapeutics, Inc. returned +7.5% against +6.9% for the S&P 500, dividends included.

DNLI vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150160Jan 26Apr 26Jul 26Oct 26DNLIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DNLI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
140.3×

Cheaper than 3% of US stocks

Price / book
3.2×

Cheaper than 29% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
97.4%

Higher than 99% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−33.9%

Higher than 27% of US stocks

Return on assets
−28.7%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Denali Therapeutics, Inc. has a market value of $2.9B and an enterprise value of $2.4B.

  • Revenue in the twelve months to 30 June 2026: $3.6M.

  • Net income over the same four quarters: −$511.5M, a −14191.2% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.84.

  • Free cash flow in the twelve months to 30 June 2026: −$466.3M.

  • Shares outstanding: 159.8M.

  • Denali Therapeutics, Inc. employs 503 people — $7K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

DNLI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DNLIDenali Therapeutics, Inc.$2.9B61
DYNDyne Therapeutics, Inc.$2.8B18
VCELVericel Corp.$2.9B98
ACADACADIA Pharmaceuticals, Inc.$2.9B84
ADMAADMA Biologics, Inc.$2.9B60
SLSSELLAS Life Sciences Group, Inc.$2.8B60
IOVAIovance Biotherapeutics, Inc.$3.1B95

Take a look at DNLI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Denali Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about DNLI

What is the DNLI stock price forecast for 2026-2027?

The 21 Wall Street analysts covering Denali Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $24 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DNLI stock a buy right now?

Of the 21 analysts covering Denali Therapeutics, Inc., 20 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Denali Therapeutics, Inc. 61 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DNLI?

As at 21 Nov 2026, Denali Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (80 of 100).

Will DNLI stock go up?

No one can know that. What the data says: the median 12-month target from 21 analysts implies +89.7% from the last close, and Ticker Nerd's factor model ranks Denali Therapeutics, Inc. 61 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DNLI stock forecast for 2030?

No analyst covering Denali Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNLI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $24 to $46 over the next 12 months.

How has DNLI stock performed over the past year?

Denali Therapeutics, Inc. returned +7.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Denali Therapeutics, Inc. do?

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.

Company

About Denali Therapeutics, Inc.

Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders. The company’s approach centers on delivering biologic and genetic medicines across the blood-brain barrier through its proprietary TransportVehicle platform, which is designed to improve access to hard-to-reach tissues in the central nervous system. Denali Therapeutics also works on product candidates across enzyme, oligonucleotide, and antibody-based programs, supporting a broader pipeline that targets both brain and body diseases. Headquartered in South San Francisco, California, Denali Therapeutics operates within the biotechnology sector and plays a role in the development of next-generation therapies for complex, high-unmet-need conditions.

CEO Dr. Ryan J. Watts Ph.D. · 503 employees · United States · https://www.denalitherapeutics.com